Secondary analysis of the phase III MAESTRO-NASH trial (966 patients with MASH, F1B-F3): on AI digital pathology, resmetirom 80 mg and 100 mg improved qFibrosis stage in 24.4% and 22.3% more patients than placebo at week 52.
Secondary analysisn = 966
Schattenberg et al. Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial